Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

01-12-2016 | Nausea and vomiting | Book chapter | Article

4. Palonosetron

Author: Lee Schwartzberg, MD, FACP

Publisher: Springer International Publishing

Login to get access

Abstract

With the recognition that the 5-hydroxytryptamine receptor was important in mediating cisplatin-induced emesis, work at several pharmaceutical companies focused on creating drugs that interfered with serotonin binding utilizing a variety of medicinal chemistry strategies. The first-generation 5-hydroxytryptamine receptor antagonists (5-HT3 RAs) ondansetron, granisetron, tropisetron, and dolasetron were structurally similar and showed activity in preventing chemotherapy-induced nausea and vomiting. However, complete response during the acute phase after cisplatin was achieved in only 50–70 % of patients and was substantially less effective in the delayed phase for control of both emesis and nausea. The first-generation 5-HT3 RAs do not improve control of delayed CINV over dexamethasone alone [1], nor does prolonged administration provide much additional benefit [2]. In addition, the first-generation 5-HT3 RAs were therapeutically equivalent with several large trials comparing these drugs to one another demonstrating similar efficacy [3, 4]. A plateau in 5-HT3 RA activity had been reached. Efforts persisted to find potentially more active agents based on the understanding of the central importance of this specific serotonin receptor in ameliorating chemotherapy-induced emesis.
Literature
1.
Geling O, Eichler HG (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol Off J Am Soc Clin Oncol 23(6):1289–1294CrossRef
2.
Hickok JT, Roscoe JA, Morrow GR et al (2005) 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 6(10):765–772PubMedCentralCrossRefPubMed
3.
Gralla RJ, Navari RM, Hesketh PJ et al (1998) Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 16(4):1568–1573
4.
Perez EA, Hesketh P, Sandbach J et al (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol Off J Am Soc Clin Oncol 16(2):754–760
5.
Clark RD, Miller AB, Berger J et al (1993) 2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists. J Med Chem 36(18):2645–2657CrossRefPubMed
6.
Yan D, Schulte MK, Bloom KE, White MM (1999) Structural features of the ligand-binding domain of the serotonin 5HT3 receptor. J Biol Chem 274(9):5537–5541CrossRefPubMed
7.
Eglen RM, Lee CH, Smith WL et al (1995) Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br J Pharmacol 114(4):860–866PubMedCentralCrossRefPubMed
8.
Wong EH, Clark R, Leung E et al (1995) The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 114(4):851–859PubMedCentralCrossRefPubMed
9.
Stoltz R, Cyong JC, Shah A, Parisi S (2004) Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 44(5):520–531CrossRefPubMed
10.
Constenla M (2004) 5-HT3 receptor antagonists for prevention of late acute-onset emesis. Ann Pharmacother 38(10):1683–1691CrossRefPubMed
11.
Stoltz R, Parisi S, Shah A, Macciocchi A (2004) Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos 25(8):329–337CrossRefPubMed
12.
Rojas C, Stathis M, Thomas AG et al (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107(2):469–478CrossRefPubMed
13.
Rojas C, Thomas AG, Alt J et al (2010) Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626(2–3):193–199CrossRefPubMed
14.
Rojas C, Slusher BS (2012) Pharmacological mechanisms of 5-HT(3) and tachykinin NK(1) receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 684(1–3):1–7CrossRefPubMed
15.
Rojas C, Raje M, Tsukamoto T, Slusher BS (2014) Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol 722:26–37CrossRefPubMed
16.
Hothersall JD, Moffat C, Connolly CN (2013) Prolonged inhibition of 5-HT(3) receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization. Br J Pharmacol 169(6):1252–1262PubMedCentralCrossRefPubMed
17.
Darmani NA, Chebolu S, Amos B, Alkam T (2011) Synergistic antiemetic interactions between serotonergic 5-HT3 and tachykininergic NK1-receptor antagonists in the least shrew (Cryptotis parva). Pharmacol Biochem Behav 99(4):573–579CrossRefPubMed
18.
Minami M, Endo T, Yokota H et al (2001) Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors. Eur J Pharmacol 428(2):215–220CrossRefPubMed
19.
Hu WP, You XH, Guan BC, Ru LQ, Chen JG, Li ZW (2004) Substance P potentiates 5-HT3 receptor-mediated current in rat trigeminal ganglion neurons. Neurosci Lett 365(2):147–152CrossRefPubMed
20.
Stathis M, Pietra C, Rojas C, Slusher BS (2012) Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol 689(1–3):25–30CrossRefPubMed
21.
Aloxi prescribing information (2015) Accessed 12.7.15 www.​Aloxi.​com/​docs/​pdf/​pi.​pdf
22.
Popovic M, Warr DG, Deangelis C et al (2014) Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 22(6):1685–1697
23.
Yavas C, Dogan U, Yavas G, Araz M, Ata OY (2012) Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 20(10):2343–2347
24.
Gonullu G, Demircan S, Demirag MK, Erdem D, Yucel I (2012) Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 20(7):1435–1439
25.
Dogan U, Yavas G, Tekinalp M, Yavas C, Ata OY, Ozdemir K (2012) Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization. Eur Rev Med Pharmacol Sci 16(4):462–468PubMed
26.
Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A (2004) Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol Off J Eur Soc Med Oncol/ESMO 15(2):330–337CrossRef
27.
Gralla R, Lichinitser M, Van Der Vegt S et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol Off J Eur Soc Med Oncol/ESMO 14(10):1570–1577CrossRef
28.
Eisenberg P, Figueroa-Vadillo J, Zamora R et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98(11):2473–2482CrossRefPubMed
29.
Celio L, Agustoni F, Testa I, Dotti K, de Braud F (2012) Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Tumori 98(3):279–286PubMed
30.
Aapro MS, Grunberg SM, Manikhas GM et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol Off J Eur Soc Med Oncol/ESMO 17(9):1441–1449CrossRef
31.
Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115–124CrossRefPubMed
32.
Aogi K, Sakai H, Yoshizawa H et al (2012) A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 20(7):1507–1514
33.
Lorusso V, Giampaglia M, Petrucelli L, Saracino V, Perrone T, Gnoni A (2012) Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 20(12):3241–3246
34.
Kris M, Tonato M, Bria E et al (2011) Consensus recommendations for the presentation of vomiting and nausea following high-emetic-risk chemotherapy. 19: Suppl 1:S25–32.
35.
Boccia R, Grunberg S, Franco-Gonzales E, Rubenstein E, Voisin D (2013) Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 21(5):1453–1460
36.
Karthaus M, Tibor C, Lorusso V et al (2015) Efficacy and safety of oral palonesetron compared with IV palonesetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC). Support Care Cancer 23(10):2917–2923.
37.
Sadaba B, del Barrio A, Campanero MA et al (2014) Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy. PLoS One 9(2):e89747PubMedCentralCrossRefPubMed
38.
NCCN Antiemesis Guidelines Version 2.2015, Accessed 12.7.15 www.​nccn.​org/​professionals/​physician_​gls/​pdf/​antiemesis.​pdf
39.
Affronti ML, Bubalo J (2014) Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy. Cancer Manag Res 6:329–337PubMedCentralCrossRefPubMed
40.
Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr, Bubalo J (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 15(11):1293–1300
41.
Musso M, Scalone R, Bonanno V et al (2009) Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 17(2):205–209
42.
Mirabile A, Celio L, Magni M, Bonizzoni E, Gianni AM, Di Nicola M (2014) Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy. Future Oncol 10(16):2569–2578CrossRefPubMed
43.
Musso M, Scalone R, Crescimanno A et al (2010) Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant 45(1):123–127CrossRefPubMed
44.
Yeh S, Lo W, Hsieh C, Bai L et al (2014) Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation. Support Care Cancer 22:1199–1206
45.
Chou CW, Chen YK, Yu YB, Chang KH, Hwang WL, Teng CL (2014) Palonosetron versus first-generation 5-hydroxytryptamine type 3 receptor antagonists for emesis prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol 93(7):1225–1232CrossRefPubMed
46.
Giralt SA, Mangan KF, Maziarz RT et al (2011) Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol Off J Eur Soc Med Oncol/ESMO 22(4):939–946CrossRef
47.
Pielichowski W, Barzal J, Gawronski K et al (2011) A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplant Proc 43(8):3107–3110CrossRefPubMed
48.
Navari RM (2013) Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs 73(3):249–262CrossRefPubMed
49.
Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V (2006) Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 4(8):403–408PubMed
50.
Herrington JD, Jaskiewicz AD, Song J (2008) Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112(9):2080–2087CrossRefPubMed
51.
Grunberg SM, Dugan M, Muss H et al (2009) Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 17(5):589–594
52.
Longo F, Mansueto G, Lapadula V et al (2012) Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. Int J Clin Pract 66(8):753–757PubMedCentralCrossRefPubMed
53.
Hashimoto H, Yamanaka T, Shimada Y et al (2013) Palonosetron (PALO) vs. granisetron (GRA) in the triplet regiment with dexamethasone (DEX) and aprepitant (APR) for preventing highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): a randomized double-blind phase III trial. J Clin Oncol. 31(suppl): 9621
54.
Takeshima N, Matoda M, Abe M et al (2014) Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 22(11):2891–2898
55.
Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY (2013) Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy. Intern Med J 43(1):73–76CrossRefPubMed
56.
Hamada S, Hinotsu S, Kawai K et al (2014) Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 22(8):2161–2166
57.
Schwartzberg L (2014) Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting. Expert Rev Pharmacoecon Outcomes Res 14(6):825–834CrossRefPubMed
58.
Ohzawa H, Miki A, Hozumi Y et al (2015) Comparison between the antiemetic effects of palonosetron and granisetron in breast cancer patients treated with anthracycline-based regimens. Oncol Lett 9(1):119–124PubMedCentralPubMed
59.
Navari R, Gray S, Kerr A (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Onc 9(5): 188–195
60.
Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M (2014) Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol Off J Am Soc Clin Oncol 32(2):101–106CrossRef
61.
Aapro M, Fabi A, Nole F et al (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol Off J Eur Soc Med Oncol/ESMO 21(5):1083–1088CrossRef
62.
Komatsu Y, Okita K, Yuki S et al (2015) Open-label, randomized, comparative phase III study on effects of reducing steroid use in combination with Palonosetron. Cancer Sci 106(7):891–895
63.
Celio L, Bonizzoni E, Bajetta E, Sebastiani S, Perrone T, Aapro MS (2013) Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 21(2):565–573
64.
Kantarjian H, Rajkumar SV (2015) Why are cancer drugs so expensive in the United States, and what are the solutions? Mayo Clin Proc 90(4):500–504CrossRefPubMed
65.
Burke TA, Wisniewski T, Ernst FR (2011) Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 19(1):131–140
66.
Craver C, Gayle J, Balu S, Buchner D (2011) Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States. J Med Econ 14(3):341–349CrossRefPubMed
67.
Avritscher EB, Shih YC, Sun CC et al (2010) Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. J Support Oncol 8(6):242–251CrossRefPubMed
68.
Faria C, Li X, Nagl N, McBride A (2014) Outcomes associated with 5-HT3-RA therapy selection in patients with chemotherapy-induced nausea and vomiting: a retrospective claims analysis. Am Health Drug Benefits 7(1):50–58PubMedCentralPubMed
69.
Balu S, Buchner D, Craver C, Gayle J (2011) Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting. Clin Ther 33(4):443–455CrossRefPubMed
70.
Broder MS, Faria C, Powers A, Sunderji J, Cherepanov D (2014) The impact of 5-HT3RA use on cost and utilization in patients with chemotherapy-induced nausea and vomiting: systematic review of the literature. Am Health Drug Benefits 7(3):171–182PubMedCentralPubMed
71.
Sepulveda-Vildosola AC, Betanzos-Cabrera Y, Lastiri GG et al (2008) Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res 39(6):601–606CrossRefPubMed
72.
Ripaldi M, Parasole R, De Simone G et al (2010) Palonosetron to prevent nausea and vomiting in children undergoing BMT: efficacy and safety. Bone Marrow Transplant 45(11):1663–1664CrossRefPubMed
73.
Nadaraja S, Mamoudou AD, Thomassen H, Wehner PS, Rosthoej S, Schroeder H (2012) Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate. Pediatr Blood Cancer 59(5):870–873CrossRefPubMed
74.
Likun Z, Xiang J, Yi B, Xin D, Tao ZL (2011) A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist 16(2):207–216PubMedCentralCrossRefPubMed
75.
Schwartzberg L, Barbour S, Morrow G et al (2014) Pooled analysis of Phase III clinical studies of palonesetron versus ondansetron, dolasetron and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer 22:469–477
76.
Herrstedt J, Roila F, ESMO guideline working group (2009) Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 20, suppl 4:156–8
77.
Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197–202CrossRefPubMed
78.
Hesketh P, Bohlke K, Lyman G et al (2015) Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol published ahead of print 11.2.15
79.
Aapro M, Molassiotis A, Dicato M et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol Off J Eur Soc Med Oncol/ESMO 23(8):1986–1992CrossRef
80.
Gilmore JW, Peacock NW, Gu A et al (2014) Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract/ Am Soc Clin Oncol 10(1):68–74CrossRef
81.
Hesketh P, Aapro M, Jordan K, Schwartzberg L et al (2015) A review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving control of chemotherapy-induced nausea and vomiting. Biomed Res Int 2015:651879
82.
Calcagnie S, Lanzarotti C, Rossi G et al (2013) Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonesetron and impact of the fixed dose combination of netupitant and palonesetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer 21(10):2879–2887
83.
Aapro M, Gralla R, Karthaus M et al (2014) Multicycle efficacy and safety of NEPA, a fixed-dose antiemetic combination of netupitant and palonesetron, in patients receiving chemotherapy of varying emetogenicity. Ann Oncol 25 (Suppl 4); IV518-IV519, Abst 1484
84.
Hesketh PJ, Rossi G, Rizzi G et al (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol Off J Eur Soc Med Oncol/ESMO 25(7):1340–1346CrossRef
85.
Spinelli T, Calcagnile S, Giuliano C et al (2014) Netupitant PET imaging and ADME studies in humans. J Clin Pharmacol 54(1):97–108PubMedCentralCrossRefPubMed
86.
Aapro M, Rugo H, Rossi G et al (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol Off J Eur Soc Med Oncol/ESMO 25(7):1328–1333CrossRef
87.
Gralla RJ, Bosnjak SM, Hontsa A et al (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol Off J Eur Soc Med Oncol/ESMO 25(7):1333–1339CrossRef
88.
Aapro M, Karthaus M, Schwartzberg L et al (2014) Phase 3 study of NEPA, a fixed dose combination of netupitant and palonosetron for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy (MEC) cycle. J Clin Oncol, 32:5S, Abstract 9502
89.
Akynzeo prescribing information (2015) Accessed 12.7.15 www.​Akynzeo.​com/​media/​Prescribing_​Information.​pdf